case_images: PMC10556648_01
case_images: Values of high-sensitivity troponin T (hsTnT) and NT pro brain natriuretic peptide (NTproBNP) during the clinical course. The red line represents the pathological threshold of hsTnT (>14 ng/L). The grey box marks the time between the first and follow-up fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) scan during the second episode of myocarditis. Magnetocardiographic measurements took place in this timeframe.
case_images: fcvm-10-1225057-g001.jpg
case_images: PMC10556648_01_fcvm-10-1225057-g001.jpg
case_images: F1
case_images: Relevant results from laboratory testing are illustrated in Figure 1.
case_images: Initial magnetocardiography (MCG) vector and MCG vector after 1 month of immunosuppressive therapy with prednisolone. The MCG vector (green plane) decreases, moving towards a score that is considered normal (<0.051) based on our previous findings and suggestive of a response to therapy.
case_images: fcvm-10-1225057-g002.jpg
case_images: PMC10556648_01_fcvm-10-1225057-g002.jpg
case_images: F2
case_images: Initial MCG measurement revealed a pathological magnetic Tbeg-Tmax vector of 0.108 [previously established cutoff value for normal Tbeg-Tmax vector <0.051; Figure 2]. An MCG follow-up measurement at that time revealed a relevant decrease of the Tbeg-Tmax vector from 0.108 to 0.036 (reference value <0.051, Figure 2), suggesting therapy response.
case_images: Magnetocardiography (MCG) vector during long-term immunosuppressive treatment throughout the second episode of inflammatory cardiomyopathy. In the time between April and August 2021, the vector normalized (<0.051 is considered normal).
case_images: fcvm-10-1225057-g003.jpg
case_images: PMC10556648_01_fcvm-10-1225057-g003.jpg
case_images: F3
case_images: MCG measurement as part of his follow-up examination (Figures 3, 4). MCG supported the recurrence of inflammatory cardiomyopathy by detecting a pathological Tbeg-Tmax vector with a value of 0.069 (reference Tbeg-Tmax <0.051, MCG measurement revealed a response to prednisolone therapy, with an improved, but still pathological, Tbeg-Tmax value of 0.056 (Figure 3, April 2021). 12-lead ECG had normalized and remained without any pathological findings during the course of the prednisolone treatment. March 2021, there was a significant reduction of tracer uptake in previously active areas. Minimal residual tracer accumulation was still present in the posterior left ventricle (Figures 4B1, B3).
case_images: Comparison of fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) to the magnetocardiography (MCG) vector before long-term immunosuppressive treatment (March 2021) and afterward (March 2022, 1 year later). (A) MCG vector: vector normalization within 1 year (<0.051 is considered normal). (B) (B.1-B.3) Illustrate the different planes of the FDG-PET-CT and cardiac tracer uptake.
case_images: fcvm-10-1225057-g004.jpg
case_images: PMC10556648_01_fcvm-10-1225057-g004.jpg
case_images: F4
case_images: MCG measurement as part of his follow-up examination (Figures 3, 4). MCG supported the recurrence of inflammatory cardiomyopathy by detecting a pathological Tbeg-Tmax vector with a value of 0.069 (reference Tbeg-Tmax <0.051, Figure 4). Fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) was used to screen for recurrent inflammation. March 2021, there was a significant reduction of tracer uptake in previously active areas. Minimal residual tracer accumulation was still present in the posterior left ventricle (Figures 4B1, B3).